Dabigatran etexilate
- Generic Name
- Dabigatran etexilate
- Brand Names
- Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C34H41N7O5
- CAS Number
- 211915-06-9
- Unique Ingredient Identifier
- 2E18WX195X
- Background
Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monit...
- Indication
Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to re...
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Venous Thromboembolism
- Associated Therapies
- -
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1878
- Registration Number
- NCT00621855
- Locations
- 🇨🇦
1160.67.11020 Boehringer Ingelheim Investigational Site, Sudbury, Ontario, Canada
🇨🇦1160.67.11018 Boehringer Ingelheim Investigational Site, London, Ontario, Canada
🇧🇪1160.67.32003 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
- Conditions
- Interventions
- First Posted Date
- 2005-10-30
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 512
- Registration Number
- NCT00246025
- Locations
- 🇯🇵
1160.50.030 Boehringer Ingelheim Investigational Site, Okayama, Okayama, Japan
🇯🇵1160.50.015 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
🇯🇵1160.50.016 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3494
- Registration Number
- NCT00168818
- Locations
- 🇦🇺
1160.48.06102 Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺1160.48.06104 Ecru, Box Hill, Victoria, Australia
🇦🇺1160.48.06110 Suite 13 level 4, Lismore, New South Wales, Australia
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2101
- Registration Number
- NCT00168805
- Locations
- 🇦🇺
1160.25.06103 Boehringer Ingelheim Investigational Site, Ringwood East, Victoria, Australia
🇦🇹1160.25.04303 Boehringer Ingelheim Investigational Site, Wels, Austria
🇨🇿1160.25.42010 Boehringer Ingelheim Investigational Site, Chomutov, Czech Republic
Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 361
- Registration Number
- NCT00157248
- Locations
- 🇺🇸
1160.42.10013 Boehringer Ingelheim Investigational Site, New Hyde Park, New York, United States
🇳🇱1160.42.31008 Gelre Ziekenhuis, locatie Juliana, Apeldoorn, Netherlands
🇩🇰1160.42.45005 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.